Optimizing Immunotherapy in Triple-Negative Breast Cancer: Reduced-Dose Folate Receptor Alpha Vaccine Shows Robust Efficacy Without Cyclophosphamide Pretreatment
Posted innews Oncology

Optimizing Immunotherapy in Triple-Negative Breast Cancer: Reduced-Dose Folate Receptor Alpha Vaccine Shows Robust Efficacy Without Cyclophosphamide Pretreatment

A Phase II trial demonstrates that a reduced-dose Folate Receptor Alpha (FRα) vaccine is safe and highly immunogenic in triple-negative breast cancer patients, achieving robust T-cell responses comparable to high-dose regimens and eliminating the need for cyclophosphamide pretreatment.
Triple-Drug Regimen with Tiragolumab and Atezolizumab Shows Superior Response in First-Line Esophageal Cancer: The MORPHEUS-EC Trial
Posted inGastroenterology news Oncology

Triple-Drug Regimen with Tiragolumab and Atezolizumab Shows Superior Response in First-Line Esophageal Cancer: The MORPHEUS-EC Trial

The phase 1b/2 MORPHEUS-EC trial demonstrates that adding the anti-TIGIT antibody tiragolumab to atezolizumab and chemotherapy significantly improves objective response rates (67.7%) in patients with previously untreated, locally advanced or metastatic esophageal cancer, providing a promising new therapeutic strategy.
Rare but Severe: Characterizing Immune Checkpoint Inhibitor-Induced Diabetes in 13,966 Trial Participants
Posted inDiabetes & Endocrinology news Oncology

Rare but Severe: Characterizing Immune Checkpoint Inhibitor-Induced Diabetes in 13,966 Trial Participants

A large-scale NCI study reveals that while immune checkpoint inhibitor-induced diabetes is rare (0.52%), it is highly morbid, often requiring hospitalization or ICU care. Risk varies significantly by treatment regimen, with combination immunotherapy increasing risk and concurrent chemotherapy appearing protective.